miR-143 and miR-145

AS oligonucleotide, experimental therapy

Koo et al. (2012) BMC Cancer 12:143

miR-1275

AS oligonucleotide, experimental therapy

Katsushima et al. (2012) J Biol Chem 2012 Jun 26 [Epub]

PTBP1

AS oligonucleotide, experimental therapy

Izaquirre et al. (2012) Mol Carcinog 51(11):895

miR-21

AS oligonucleotide, experimental therapy

Zhou et al. (2012) Zhonqhua Znonq Liu Za Zhi 33(10):74

ATM

AS vector, experimental therapy

Chuah et al. (2012) Int J Oncol 40(6):1963

miR-143 &-145

AS vector, experimental therapy

Koo et al. (2012) BMC Cancer 12:143

18-kDa-TSPO

AS vector, experimental therapy

Veenman et al. (2012) Pharmacogenet Genomics 22(8):606

miR-1275

AS oligonucleotide, experimental therapy

Katsushima et al. (2012) J Biol Chem 287(33):27396

miR-21

AS oligonucleotide, experimental therapy

Wong et al. (2012) Anticancer Res 32(7):2835

Metallo-thionein 1E

AS vector, experimental therapy

Ryu et al. (2012) Int J Oncol 41(4):1305

miR-92a

AS oligonucleotide, experimental therapy

Niu et al. (2012) Oncol Rep 28(5):1771

14-3-3-beta

AS vector, experimental therapy

Park et al. (2012) Neurol Res 34(9):893

MMP-9

AS vector, experimental therapy

Sun et al. (2013) 29(1):83

miR106b

AS oligonucleotide, experimental therapy

Zhang et al. (2013) J Neuro-oncol 112(2):179

miR-30a-5p

AS oligonucleotide, experimental therapy

Jia et al. (2013) PLoS One 8(1):e55008

IGF-I

AS vector, experimental therapy

Pan et al. (2013) PLoS One 8(3):e58428

EGF-R

AS vector, experimental therapy

Kalman et al. (2013) Neuromolecular Med 15(2):420

miR-21

AS oligonucleotide, experimental therapy

Costa et al. (2013) Mol Ther Nucleic Acids 2:e100.